TP53 and cancer: Nutlin‐3a occupies the p53‐binding pocket to abrogate p53‐MDM2 interaction, and was originally developed for cancer therapy.[33] Moreover, Nutlin‐3a interferes with the binding between MDM2 and hypoxia‐inducible factor‐α or p73 in the absence of p53.[41, 42] In silico prediction indicates two putative binding sites of MDM2 in ApoB, and we confirm that MDM2 and ApoB interact via the binding sites L347/F348/L351 and L3684/W3685/L3688.